On April 18, 2026, President Donald Trump signed a landmark executive order in the Oval Office designed to dramatically accelerate the research and regulatory review of psychedelic drugs, most notably the controversial compound ibogaine.

Employees across the massive U.S. Health and Human Services Department began receiving notices of dismissal on Tuesday in an overhaul ultimately expected to lay off up to 10,000 people.